AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9445630
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with paclitaxel and docetaxel
Trial: 9445630
Drug: Selective aromatase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective aromatase inhibitors, new antigestagens, and antiestrogens
Trial: 9445630
Drug: Dose intensity
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose intensity concepts with growth factors and peripheral stem cell support
Trial: 9445630
Drug: Humanized monoclonal
RxNorm normalized name: Humanized monoclonal antibody Hu1B7
DrugBank: Humanized monoclonal antibody Hu1B7 (DB17828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humanized monoclonal antibody against CerbB‐2 receptors
Trial: 8383403
Drug: 50% combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% combination of alcuronium (0.125 mg.kg‐1) and tubocurarine (0.255 mg.kg‐1)
Trial: 8383403
Drug: Alcuronium alone
RxNorm normalized name: alcuronium
DrugBank: Alcuronium (DB13648)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcuronium alone (0.25 mg.kg‐1)
Trial: 8383403
Drug: Tubocurarine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tubocurarine alone (0.51 mg.kg‐1)
Trial: 8383403
Drug: 33% combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33% combination of alcuronium and tubocurarine
Trial: 3549739
Drug: Intra-aortic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-aortic administration of protamine sulphate
Trial: 3549739
Drug: Intra-right atrial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-right atrial administration of protamine sulphate
Trial: 21218307
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for depression
Trial: 31347012
Drug: dDAVP (lyophilizate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dDAVP (lyophilizate 120 μg)
Trial: 31347012
Drug: New age-
RxNorm normalized name: TITANIUM DIOXIDE 66.2 mg in 1 g / OCTINOXATE 25 mg in 1 g TOPICAL CREAM [Anew Age-Transforming Concealer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New age- and weight-based dosing regimen
Trial: 29952004
Drug: UTTR1147A (IL-22Fc)
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UTTR1147A (IL-22Fc) administered intravenously (i.v.) at doses of 1-120 μg/kg
Trial: 29952004
Drug: UTTR1147A (IL-22Fc)
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UTTR1147A (IL-22Fc) administered subcutaneously (s.c.) at doses of 3-120 μg/kg
Trial: 28086766
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) intervention, consisting of 6 sessions (1 individual and 5 group) offered by a psychologist, in addition to treatment as usual.
Trial: 26101366
Drug: 9-valent HPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-valent HPV vaccine (3-dose regimen at day 1, month 2, month 6)
Trial: 17065355
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose >150 mg/dl
Trial: 17065355
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose <110 mg/dl
Trial: 15170708
Drug: Intracoronary abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary abciximab treatment
Trial: 15170708
Drug: Usual abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual abciximab administration
Trial: 9841947
Drug: Conventional flap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional flap surgery (previous treatment)
Trial: 9841947
Drug: Matched control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched control patients who underwent conventional treatment alone
Trial: 8135881
Drug: Intramuscular glucosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular glucosamine sulfate 400 mg twice a week for 6 weeks
Trial: 26307858
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment for chronic neuropathic pain
Trial: 23543140
Drug: Silodosin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silodosin (8 mg/daily for a maximum of 4 weeks)
Trial: 23543140
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (2 L of water daily)
Trial: 19436289
Drug: Non-stent treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-stent treatments
Trial: 16454836
Drug: Etoricoxib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib (60 to 120 mg tablet once a day)
Trial: 16454836
Drug: Placebo (tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (tablet once a day)
Trial: 15039128
Drug: Aggressive pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive pharmacological treatment (using statins, beta-blockers, ACE-inhibitors, and aspirin)
Trial: 12604023
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of zafirlukast twice a day
Trial: 12604023
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of budesonide twice a day
Trial: 12604023
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of zafirlukast twice a day and 400 mg of budesonide twice a day
Trial: 8232703
Drug: Conventional supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional supportive treatment
Trial: 2446759
Drug: Isoprinosine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoprinosine (50 mg/kg) as pulse immunotherapy, schedule A: 5 days every 15 days
Trial: 2446759
Drug: Isoprinosine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoprinosine (50 mg/kg) as pulse immunotherapy, schedule B: 5 days every 15 days for 2 months, then 5 days every 2 months
Trial: 30213617
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (n=5) received weekly boxes of fruits and vegetables and dietary counseling to increase consumption to 8 to 10 daily servings for 12 weeks.
Trial: 14600926
Drug: CK‐MB increase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CK‐MB increase > 50 IU/ml (group 1, n = 9)
Trial: 14600926
Drug: CK‐MB levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CK‐MB levels </= 50 IU/ml (group 2, n = 27)
Trial: 14600926
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (CK‐MB > 50 IU/ml)
Trial: 14600926
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (CK‐MB </= 50 IU/ml)
Trial: 10831545
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (triptorelin) with HMG
Trial: 10831545
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (buserelin) with HMG
Trial: 10831545
Drug: GnRH agonists
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonists (triptorelin or buserelin) with HMG
Trial: 9104522
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg granisetron (approximately 60 micrograms.kg‐1)
Trial: 9104522
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg droperidol (approximately 25 micrograms.kg‐1)
Trial: 8182634
Drug: Home physiotherapy
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home physiotherapy treatment program
Trial: 8182634
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (previously withheld treatment)
Trial: 3372681
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg orally) + Alcohol
Trial: 3372681
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg orally) + Placebo
Trial: 3372681
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg orally)
Trial: 31063475
Drug: Daclatasvir (DCV)
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclatasvir (DCV) and Sofosbuvir (SOF) therapy
Trial: 16405734
Drug: Drip-push (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drip-push (4 modules weekly over 10 weeks by email)
Trial: 16405734
Drug: Drip-pull (modules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drip-pull (modules accessible on website with 4 reminders weekly for 10 weeks)
Trial: 12922085
Drug: Full adult
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full adult dose of tick-borne encephalitis vaccine
Trial: 12922085
Drug: Half adult
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half adult dose of tick-borne encephalitis vaccine
Trial: 1832424
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g glucose dose
Trial: 18438908
Drug: Cumulative prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cumulative prednisone dosage in multiple flares subgroup: 7.9 gm
Trial: 18438908
Drug: Cumulative prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cumulative prednisone dosage in single flare subgroup: 6.0 gm
Trial: 18438908
Drug: Cumulative prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cumulative prednisone dosage in remission subgroup: 3.9 gm
Trial: 16854754
Drug: Combined low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combined low-dose azathioprine (0.6-0.75 mg/kg) and oral PUVA therapy
Trial: 16854754
Drug: Oral PUVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PUVA therapy alone
Trial: 15331546
Drug: Gastric inhibitory
RxNorm normalized name: Gastric inhibitory peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric inhibitory polypeptide (GIP) infusion (2 pmol. kg(‐1). min(‐1), 60‐115 min)
Trial: 11557836
Drug: Lifestyle treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle treatments
Trial: 8427943
Drug: Temocapril HCl
RxNorm normalized name: temocapril HCl
DrugBank: Temocapril (DB08836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temocapril HCl (0.5 mg)
Trial: 8427943
Drug: Temocapril HCl
RxNorm normalized name: temocapril HCl
DrugBank: Temocapril (DB08836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temocapril HCl (1.0 mg)
Trial: 8427943
Drug: Temocapril HCl
RxNorm normalized name: temocapril HCl
DrugBank: Temocapril (DB08836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temocapril HCl (2.0 mg)
Trial: 3326213
Drug: Standard enteric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard enteric coated preparation
Trial: 20639713
Drug: Muffins containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muffins containing 4 mg Fe as ferrous fumarate with orange juice (25 mg ascorbic acid)
Trial: 20639713
Drug: Muffins containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muffins containing 4 mg Fe as ferrous fumarate with apple juice (no ascorbic acid)
Trial: 18348735
Drug: Narconon drug
RxNorm normalized name: Narcogen
DrugBank: Trichloroethylene (DB13323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narconon drug education curriculum
Trial: 18348735
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (received drug education after the six-month follow-up)
Trial: 17288232
Drug: Antinicotine vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antinicotine vaccines (TA-NIC, NicVAX, CYT002-NicQb)
Trial: 12707149
Drug: HES 130/0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES 130/0.4 (n = 16) at doses of up to 70 mL x kg(‐1) x d(‐1)
Trial: 12707149
Drug: HES 200/0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES 200/0.5 (n = 15) at doses of up to 33 mL x kg(‐1) x d(‐1) followed by human albumin
Trial: 9321529
Drug: All-trans-retinoic acid
RxNorm normalized name: all-trans-Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans-retinoic acid (induction treatment)
Trial: 9321529
Drug: Chemotherapy (daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (daunorubicin plus cytarabine) (induction treatment)
Trial: 9321529
Drug: All-trans-retinoic acid
RxNorm normalized name: all-trans-Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans-retinoic acid (maintenance treatment)
Trial: 9321529
Drug: Chemotherapy (maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (maintenance treatment)
Trial: 9321529
Drug: All-trans-retinoic acid
RxNorm normalized name: all-trans-Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans-retinoic acid (induction and maintenance treatment)
Trial: 8416719
Drug: Outpatient chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient chemotherapy
Trial: 3546124
Drug: Oral diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diclofenac (prostaglandin inhibitor) for 1 week after splintage removal
Trial: 14754980
Drug: Chlorpheniramine (first-generation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine (first-generation antihistamine)
Trial: 14754980
Drug: Cetirizine (second-generation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (second-generation antihistamine)
Trial: 9379690
Drug: Octreotide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (4 months therapy)
Trial: 3022664
Drug: Desipramine-lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desipramine-lithium carbonate or lithium carbonate-tranylcypromine sulfate combination treatment
Trial: 31599351
Drug: CBT +
RxNorm normalized name: Cannabidiol
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CBT + treatment as usual (TAU)
Trial: 22864399
Drug: Persistence on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Persistence on the stress-challenge task before initiating buprenorphine treatment
Trial: 22864399
Drug: Antidepressant and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant and placebo groups
Trial: 15854186
Drug: Cophenylcaine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cophenylcaine nasal spray
Trial: 12162475
Drug: Film-coated tablets
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Film-coated tablets (FCT)
Trial: 17851680
Drug: Aqueous solution
RxNorm normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous solution (AS)
Trial: 6411230
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous insulin infusion starting at 2 U/hour for adolescents, 4 U/hour for adults, and 6 U/hour for patients with acromegaly
Trial: 30582194
Drug: Media Smart-Targeted
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Media Smart-Targeted (MS-T) program (9-module program released weekly)
Trial: 28477269
Drug: Self-administered questionnaires
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered questionnaires regarding awareness and knowledge of cervical cancer
Trial: 28477269
Drug: Self-administered questionnaires
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered questionnaires regarding attitudes towards cervical cancer screening and prevention
Trial: 17426065
Drug: Anti-TNF treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF treatments (etanercept, infliximab, adalimumab) in RCTs
Trial: 15115499
Drug: PUVA (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA (twice weekly for 3 months)
Trial: 15115499
Drug: ECP (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECP (once monthly for 6 months at relapse)
Trial: 9149168
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus surgery plus radiotherapy (arm A)
Trial: 9149168
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus radiotherapy alone (arm B)
Trial: 27914503
Drug: TAVR with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAVR with Edwards SAPIEN 3 Transcatheter Heart Valve plus optimal heart failure therapy (OHFT)
Trial: 27914503
Drug: Optimal heart
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal heart failure therapy (OHFT) alone
Trial: 23233021
Drug: Bumetanide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide (1 mg daily)
Trial: 16398803
Drug: Topical nitroglycerin
RxNorm normalized name: nitroglycerin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nitroglycerin (GTN)
Trial: 14514130
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg LJP 394 weekly for 16 weeks followed by three 12-week treatment cycles of 50 mg LJP 394 weekly
Trial: 8991843
Drug: Procedures with
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Procedures with minimal endometrial injury (e.g., syneciolysis, hysteroscopic proximal tubal catheterisation)
Trial: 8991843
Drug: Ablative procedures
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative procedures (e.g., resection of myoma, endometrium ablation, septum resection)
Trial: 30195616
Drug: Direct-acting antiviral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antiviral regimen
Trial: 19727956
Drug: No antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiviral treatment
Trial: 26762481
Drug: Heparin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin with or without tirofiban
Trial: 17385265
Drug: L-NAME (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NAME (1 mg/kg) administered intravenously over 60 minutes
Trial: 17385265
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously over 60 minutes
Trial: 11978255
Drug: roxithromycin 300
RxNorm normalized name: roxithromycin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin 300 mg once a day for 10 days
Trial: 11978255
Drug: amoxicillin 500
RxNorm normalized name: amoxicillin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amoxicillin 500 mg three times per day for 10 days
Trial: 7897786
Drug: Multifaceted intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifaceted intervention with increased intensity and frequency of visits (visits with primary care physician and psychiatrist) and continued surveillance of adherence to medication regimens.
Trial: 2087821
Drug: Anthraquinone containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthraquinone containing laxative
Trial: 2087821
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no anthraquinone laxative)
Trial: 16987710
Drug: No antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiretroviral therapy
Trial: 12631652
Drug: Baclofen (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (acute administration for 24 hours)
Trial: 12631652
Drug: Baclofen (chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (chronic administration for four weeks, 10 mg four times daily)
Trial: 12631652
Drug: Placebo (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (acute administration for 24 hours)
Trial: 12631652
Drug: Placebo (chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (chronic administration for four weeks)